‘WeChat WeQuit’ Smoking Cessation Program

Overview

This proposed project is to assess whether WeChat-based smoking cessation interventions ('WeChat WeQuit' program) will be effective at helping people in China who smoke, to quit.

Full Title of Study: “The Efficacy of WeChat Based Interventions (‘WeChat WeQuit’ Program) for Smoking Cessation in China: a Randomized Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Health Services Research
    • Masking: Single (Participant)
  • Study Primary Completion Date: November 16, 2022

Interventions

  • Behavioral: Cognitive and Behavioral Intervention
    • Participants who allocate to the intervention group will receive regular smoking cessation related information by professional team.

Arms, Groups and Cohorts

  • Experimental: Intervention Group
    • Participants in the intervention group will receive the ‘WeChat WeQuit’ program from the WeChat subscription account. The period for intervention was 14 weeks, including 2-week quiting preparation intervention and 12-week postquit intervention. The number of messages/pictures/audios received by participants will gradually decrease (will be intensively sent to them during 2-week prequit and 4-week postquit, and less intensively during 5-week to 12-week postquit), and follow-up questionnaires were sent only once a month in 14-28 weeks (week 16, 20, and 26 after the quit date). A WeChat group was created for answering questions from participants, and sharing the latest resources related to quitting smoking, and promoting communication between participants.
  • No Intervention: Control Group
    • Control group participants will not receive any smoking cessation messages by professional team. They will receive messages of thanking them for being in the study and reminding them of the time until their free month at the end of follow up. In order to measure the main two outcomes (self-reported continuous smoking abstinence and point prevalence of abstinence), continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last week if they are still smoking will be checked at week 1, 4, 8, 12, 16, 20 and 26 points.

Clinical Trial Outcome Measures

Primary Measures

  • Biochemically Validated Continuously Abstinence
    • Time Frame: 26 weeks
    • The primary outcome will be biochemical validation of self-reported 26-week continuous smoking abstinence

Secondary Measures

  • Self-reported 7-day Point Abstinence
    • Time Frame: 26 weeks
    • Self-reported 7-day point-prevalence abstinence at week 1, 4, 8, 12, 16, 20 and 26 after quit date.
  • Self-reported Continuous Abstinence
    • Time Frame: 26 weeks
    • Self-reported continuous smoking abstinence rate at weeks 4, 8, 12, 16, 20, and 26 after the quit date.

Participating in This Clinical Trial

Inclusion Criteria

1. Daily Chinese cigarette smokers. 2. 18 years of age and older living. 3. Being able to read and write in Chinese. 4. Owning a smartphone and knowing how to use WeChat. 5. Willing to make an attempt to quit smoking in the next month. 6. Willing to provide informed consent to participate in the study. Exclusion Criteria:

1. Nonsmokers. 2. Smokers without attempt to quit. 3. Below 18 years old. 4. Unable to use smartphone and WeChat. 5. Unable to read and write in Chinese.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Sir Run Run Shaw Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Yanhui Liao, Attending Psychiatrist – Sir Run Run Shaw Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.